{"id":245911,"date":"2026-10-24T17:05:58","date_gmt":"2026-10-24T22:05:58","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/10\/a-precision-t-cell-therapy-stalls-treatment-resistant-cancers-in-clinical-trial"},"modified":"2026-10-24T17:05:58","modified_gmt":"2026-10-24T22:05:58","slug":"a-precision-t-cell-therapy-stalls-treatment-resistant-cancers-in-clinical-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/10\/a-precision-t-cell-therapy-stalls-treatment-resistant-cancers-in-clinical-trial","title":{"rendered":"A precision T-cell therapy stalls treatment-resistant cancers in clinical trial"},"content":{"rendered":"\n<p>Early results of the <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05592626\" target=\"_blank\">first clinical trial<\/a> to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy.<\/p>\n<p>A study led by researchers at the National Institutes of Health (NIH), Mass General Brigham and Memorial Sloan Kettering found that, at optimal doses, invika was well tolerated and, in patients whose solid tumors had resisted standard immunotherapy, halted disease progression in most and shrank tumors in some. The work is <a href=\"https:\/\/www.nature.com\/articles\/s41591-026-04711-0\" target=\"_blank\">published<\/a> in the journal Nature Medicine.<\/p>\n<p>\u201cPatients whose tumors are advanced\u2014particularly tumors that don\u2019t respond well to immunotherapy\u2014often have their backs against a wall. Few options remain once you reach that point, but these results highlight a more precise means of stimulating antitumor immunity that could provide another solution,\u201d said co-corresponding author James Gulley, clinical director at the Center for Cancer Research (CCR), part of NIH\u2019s National Cancer Institute (NCI).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy. A study led by researchers at the National Institutes of Health (NIH), Mass General Brigham and Memorial Sloan Kettering found [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1495],"tags":[],"class_list":["post-245911","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-health"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=245911"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/245911\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=245911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=245911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=245911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}